

## PRODUCT INFORMATION

<b>Clone ID</b>	1G9
<b>Target</b>	CL2A
<b>Synonyms</b>	N.A.
<b>Host Species</b>	Rabbit
<b>Description</b>	PE-conjugated Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
<b>Delivery</b>	3-4 weeks
<b>Uniprot ID</b>	N.A.
<b>IgG type</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	N.A.
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Liquid□PBS with 0.05% Proclin300, 1% BSA
<b>Storage &amp; Shipping</b>	Store at 2°C-8°C for 6 months
<b>Background</b>	CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
<b>Usage</b>	Research use only
<b>Conjugate</b>	PE-conjugated

